Expression of interest

Expression of interest

Driving equitable access to fit-for-purpose antigen-detecting rapid diagnostic tests for COVID-19

FIND is leading a call for expressions of interest (EOI) to accelerate the availability and manufacturing scale-up of rapid diagnostic tests for the detection of SARS-CoV-2 antigens. This EOI has been prepared in the context of the Access to COVID-19 Tools (ACT) Accelerator Diagnostics Pillar, launched by FIND and Unitaid, and supports the work plans of two working groups within the pillar: “R&D of tests & digital tools” (led by the Bill & Melinda Gates Foundation and the Praesens Foundation) and “Market readiness” (led by Unitaid and FIND).

This EOI opened on 4 July 2020, and the first deadline for receipt of submissions closed on 24 July 2020. Applications are now invited before a second deadline of 24 August 2020, 23:59 CET. Subject to additional funding commitments, a rolling process for further submissions will then be established to enable inclusion of manufacturers who are not at a stage where they can submit a proposal to meet the original deadlines.

Innovators, RDT developers, IVD manufacturers and LMIC-based diagnostic stakeholders are invited to apply.

A range of funding mechanisms could be applied according to the needs of each business case.

DOWNLOAD FULL EOI (PDF)

Background

Since the beginning of the COVID-19 pandemic, molecular testing has played a critical role in the management of suspected cases as well as contact tracing worldwide. Testing capacity, however, remains highly centralized, and often insufficient to meet the current demand. While countries in all regions have experienced these challenges, the needs are more acute in low- and middle-income countries (LMICs), where fragile health systems and exclusive reliance on global supply chains have often left LMICs unable to access much-needed tests. This situation is further compounded by the lack of reliable, affordable and easy-to-use rapid tests for clinical diagnosis of COVID-19. While such tests would be beneficial to high-income countries (HICs), they are critical for establishing testing programmes in LMICs.

An estimated 500 million COVID-19 diagnostic tests will be needed in LMICs over the next 12 months, 75% of which in decentralized settings (i.e. primary healthcare, community-level care, hospital triage). There is emerging consensus about the important role that SARS-CoV-2 antigen-detecting rapid diagnostic tests (Ag RDTs) will play in filling this gap, as the primary diagnostic for active infection detection in decentralized settings where timely molecular testing is not available.

While the situation is dynamic, several market challenges stand in the way of supplying LMICs with fit-for-purpose Ag RDTs:

Scope

This EOI aims to fill current diagnostic gaps in the detection of active SARS-CoV-2 infection for case management and contact tracing purposes in decentralized settings. In this context, a test that detects the virus in a user-friendly, field-appropriate format is desirable. While both point-of-care nucleic acid testing platforms and Ag RDTs would be appropriate in these settings, this call is focussed on accelerating supply and availability of quality-assured and regulatory-approved fit-for-purpose Ag RDTs.

The ACT-Accelerator Diagnostics Pillar (ACT-A Dx) will engage end-to-end, from the development and deployment process to driving access to these fit-for-purpose Ag RDTs. This will include accelerating development, facilitating regulatory approvals, and increasing production capacity, addressing supply chain challenges, establishing mechanisms (such as volume guarantees) to de-risk the market, and strengthening local capacity for development and deployment of new tests within national testing strategies. This EOI is just one of several mechanisms being developed by ACT-A Dx, and is focused on the downstream activities of product development and manufacturing scale-up.

Proposals and business partnerships are sought in two areas:

  • Accelerating development and market entry of improved, quality-assured SARS-CoV-2 Ag RDTs for expanded use in LMICs
  • Rapidly creating the supply conditions (manufacturing capacity, diversity of supplier base, affordability) to meet the needs of LMICs

Benefits

An initial budget envelope of up to US$40 million of grant funding, to be made available by FIND and Unitaid and supplemented by loan funding from development banks, could support at least 2–4 proposals that offer best value for money. As additional funding becomes available, further proposals will be considered. Funding negotiations will be conducted independently for each proposal, and will be tailored to the applicant’s needs and the specifics of each business case. Funding could take many forms, such as R&D grant funding, loans for infrastructure scale up, licensure agreements, and/or longer-term volume commitments.

Alongside financial support, the direct benefits of this programme include partnership opportunities and advisory/technical support.

Interested parties

Proposals are sought from innovators, RDT developers, IVD manufacturers, and LMIC-based diagnostic stakeholders interested in:

  • Expanding their own production capacity, with commitment to LMIC supply
  • Supporting geographic diversification of manufacturing in one or more LMIC regions with local partnerships, including (but not limited to) contract manufacturing for open-label products
  • Partnering with readily available high-quality manufacturing capacity globally, or offering their own excess production capacity to other developers
  • Licensing and/or technology transfer

Timelines & governance

This EOI opened on 4 July 2020, and the first deadline for receipt of submissions closed on 24 July 2020. Applications are now invited before a second deadline of 24 August 2020, 23:59 CET. Subject to additional funding commitments, a rolling process for further submissions will then be established to enable inclusion of manufacturers who are not at a stage where they can submit a proposal to meet the original deadlines.

For full details on how to apply, please refer to the full EOI (PDF).

FIND is leading this EOI on behalf of ACT-A Dx; management, evaluation and selection of proposals will be conducted according to FIND governance, policies and procedures. Proposals and partnerships selected for funding negotiations will then engage with the corresponding donors, who will follow their own procedures for contracting and monitoring.

More information

For more information please contact us.

Q&A

online workshop co-hosted by find & unitaid, 10 july 2020 @ 07h00

online workshop co-hosted by find & unitaid, 10 july 2020 @ 17h00

DOWNLOAD FULL EOI (PDF)

About the Access to COVID-19 Tools (ACT) Accelerator

The ACT Accelerator is a ground-breaking global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines. It was set up in response to a call from G20 leaders in March and launched by the WHO, EC, France and the Bill & Melinda Gates Foundation in April 2020.

The ACT-Accelerator is not a decision-making body or a new organization, but works to speed up collaborative efforts among existing organizations to end the pandemic. It is a framework for collaboration that has been designed to bring key players around the table with the goal of ending the pandemic as quickly as possible by reducing COVID-19 mortality and severe disease through the accelerated development, equitable allocation, and scaled up delivery of tests, treatments and vaccines, thereby protecting health systems and restoring societies and economies in the near term. It draws on the experience of leading global health organizations which are tackling the world’s toughest health challenges, and who, by working together, are able to unlock new and more ambitious results against COVID-19. Its members share a commitment to ensure all people have access to all the tools needed to defeat COVID-19 and to work with unprecedented levels of partnership to achieve it.

The ACT-Accelerator has four pillars of work: diagnostics, therapeutics, vaccines and the health system connector. Cross-cutting all of these is the workstream on access & allocation.


Quick links

x
x